Lipid nanocarriers (LNC) and their applications in ocular drug delivery

Current Medicinal Chemistry

Volumn 22, Issue 13, 2015, Pages 1589-1602

  Puglia, Carmelo ^a   Offerta, Alessia ^a   Carbone, Claudia ^a   Bonina, Francesco ^a   Pignatello, Rosario ^a   Puglisi, Giovanni ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Drug delivery systems; Lipid drug conjugates (LDC); Nanomedicine; Nanostructured lipid carriers (NLC); Ophthalmology; Solid lipid nanoparticles (SLN)

Indexed keywords

AGENTS ACTING ON THE EYE; ALPHA TOCOPHEROL; ANTIGLAUCOMA AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; ARTIFICIAL TEAR; ASCORBIC ACID; AZITHROMYCIN; CYCLOSPORIN A; DICLOFENAC; DIFLUPREDNATE; FLURBIPROFEN; GATIFLOXACIN; GENE THERAPY AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; LATANOPROST; LIPID; LIPID DRUG CONJUGATE; LIPID NANOCARRIER; LIPOSOME; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; NATURAL PRODUCT; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOL; SOLID LIPID NANOPARTICLE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG CARRIER; NANOMATERIAL;

ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; EYE DISEASE; HUMAN; INTRAOCULAR PRESSURE; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; ZETA POTENTIAL; ANIMAL; CHEMISTRY; EYE; EYE DISEASES; GENETICS; METABOLISM; NANOMEDICINE; PROCEDURES;

ANIMALS; DRUG CARRIERS; EYE; EYE DISEASES; HUMANS; LIPIDS; NANOMEDICINE; NANOSTRUCTURES;

EID: 84931281534     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150209152259     Document Type: Article

References (112)

1. Lang, J.C. Ocular drug delivery conventional ocular formulations. Adv. Drug Deliv. Rev., 1995, 16, 39-43.
2. Zarbin, M.A.; Montemagno, C.; Leary, J.F.; Ritch, R. Nanomedicine in ophthalmology: The new frontier. Am. J. Ophthalmol., 2010, 150, 144-162.
3. de la Fuente, M.; CyAba, N.; Garcia-Fuentes, M.; Alonso, M.J. Nanoparticles as protein and gene carriers to mucosal surfaces. Nanomedicine (Lond), 2008, 3, 845-857.
4. Mainardes, R.M.; Urban, M.C.; Cinto, P.O.; Khalil, N.M.; Chaud, M.V.; Evangelista, R.C.; Gremiao, M.P. Colloidal carriers for ophthalmic drug delivery. Curr. Drug Targets, 2005, 6, 363-371.
5. Vandervoort, J.; Ludwig, A. Preparation and evaluation of drugloaded gelatine nanoparticles for topical ophthalmic use. Eur. J. Pharm. Biopharm., 2004, 57, 251-261.
6. Bourges, J.L.; Gautier, S.E.; Delie, F.; Bejjani, R.A.; Jeanny, J.C.; Gurny, R.; BenEzra, D.; Behar-Cohen, F. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Vis. Sci., 2003, 44, 3562-3569.
7. Kayser, O.; Lemke, A.; Hernandez-Trejo, N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr. Pharm. Biotechnol., 2005, 6, 3-5.
8. Sanchez, A.; Alonso, M.J. Nanoparticular carriers for ocular drug delivery. In: Nanoparticulates as drug carriers; Torchilin, V.P. Ed; Imperial College Press: London, UK, 2006; pp. 649-673.
9. Hagigit, T.; Abdulrazik, M.; Orucov, F.; Valamanesh, F.; Hagedorn, M.; Lambert, G.; Behar-Cohen, F.; Benita, S. Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye. J. Control. Release, 2010, 145, 297-305.
10. Hironaka, K; Inokuchi, Y; Fujisawa, T; Shimazaki, H; Akane, M; Tozuka, Y; Tsuruma, K; Shimazawa, M; Hara, H; Takeuchi, H. Edaravone-loaded liposomes for retinal protection against oxidative stress-induced retinal damage. Eur. J. Pharm. Biopharm., 2011, 79, 119-125.
11. Zhang, J.; Wang, S.L. Topical use of Coenzyme Q(10)-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. Int. J. Pharm., 2009, 372, 66-75.
12. Puglia, C.; Bonina, F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin. Drug Deliv., 2012, 9(4), 429-441.
13. Carbone, C.; Cupri, S.; Leonardi, A.; Puglisi, G.; Pignatello, R. Lipid-based nanocarriers for drug delivery and targeting: A patent survey of methods of production and characterization. Pharm. Pat. Anal., 2013, 2, 665-77.
14. Snell, R.S.; Lemp, M.A. Clinical Anatomy of the Eye. Wiley Online Library, 2013; DOI: 10.1002/9781118690987.
15. Souto, E.B.; Müller, R.H. Lipid nanoparticles: Effect on bioavailability and pharmacokinetic changes. Handb. Exp. Pharmacol., 2010, 197, 115-141.
16. Souto, E.B.; Doktorovova, S.; Gonzalez-Mira, E.; Egea, M.A.; Garcia, M.L. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr. Eye Res., 2010, 35, 537-552.
17. del Pozo-Rodríguez, A.; Delgado, D.; Gascón, A.R.; Solinís, M.A. Lipid nanoparticles as drug/gene delivery systems to the retina. J. Ocul. Pharmacol. Ther., 2013, 29(2), 173-188.
18. Puglia, C.; Offerta, A.; Rizza, L.; Zingale, G.; Bonina, F.; Ronsisvalle, S. Optimization of curcumin loaded lipid nanoparticles formulated using high shear homogenization (HSH) and ultrasonication (US) methods. J. Nanosci. Nanotechnol., 2013, 13(10), 6888-6893.
19. Leonardi, A.; Bucolo, C.; Romano, G.L.; Platania, C.B.; Drago, F.; Puglisi, G.; Pignatello, R. Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. Int. J. Pharm., 2014, 470(1-2), 133-140.
20. Montenegro, L.; Campisi, A.; Sarpietro, M.G.; Carbone, C.; Acquaviva, R.; Raciti, G.; Puglisi, G. In vitro valuation of idebenoneloaded solid lipid nanoparticles for drug delivery to the brain. Drug. Dev. Ind. Pharm., 2011, 37(6), 737-46.
21. Montenegro, L.; Sinico, C.; Castangia, I.; Carbone, C.; Puglisi, G. Idebenone-loaded solid lipid nanoparticles for drug delivery to the skin: in vitro evaluation. Int. J. Pharm., 2012, 434(1-2), 169-74.
22. Müller, R.H.; Shegokar, R.; Keck, C.M. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr. Drug Discov. Technol., 2011, 8(3), 207-227.
23. Shekunov, B.Y.; Chattopadhyay, P.; Tong, H.H.; Chow, A.H. Particle size analysis in pharmaceutics: principles, methods and applications. Pharm. Res., 2007, 24(2), 203-227.
24. Gonzalez-Mira, E.; Egea, M.A.; Garcia, M.L.; Souto, E.B. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf. B Biointerfaces, 2010, 81(2), 412-421.
25. Araujo, J.; Gonzales, E.; Egea, M.A.; Garcia, M.L.; Souto, E.B. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine, 2009, 5(4), 394-401.
26. Puglia, C., Blasi, P., Rizza, L., Schoubben, A., Bonina, F., Rossi, C., Ricci, M. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int. J. Pharm., 2008, 357(1-2), 295-304.
27. Puglia, C.; Damiani, E.; Offerta, A.; Rizza, L.; Tirendi, G.G.; Tarico, M.S.; Curreri, S.; Bonina, F.; Perrotta, R.E. Evaluation of nanostructured lipid carriers (NLC) and nanoemulsions as carriers for UV-filters: characterization, in vitro penetration and photostability studies. Eur. J..Pharm. Sci., 2014, 51, 211-217.
28. Bunjes, H.W.K.; Kock, M.H.J. Crystallization tendency and polymorphic transitions in trigliceride nanoparticles. Int. J. Pharm., 1996, 129, 159-173.
29. Freitas, C.; Muller, R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm., 1999, 47, 125-132.
30. Müller, R.H.; Radtke, M.; Wissing, S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm., 2002, 242, 121-128.
31. Carbone, C.; Campisi, A.; Musumeci, T.; Raciti, G.; Bonfanti, R.; Puglisi, G. FA-loaded lipid drug delivery systems: preparation, characterization and biological studies. Eur. J. Pharm. Sci., 2014, 52, 12-20.
32. Trotta, M.; Cavalli, R.; Carlotti, M.E.; Battaglia, L.; Debernardi, F. Solid lipid micro-particles carrying insulin formed by solvent-inwater emulsion-diffusion technique. Int. J. Pharm., 2005, 288(2), 281-288.
33. Gallarate, M.; Trotta, M.; Battaglia, L.; Chirio, D. Preparation of solid lipid nanoparticles from W/O/W emulsions: preliminary studies on insulin encapsulation. J. Microencapsul., 2009, 26(5), 394-402.
34. Puglia, C.; Offerta, A.; Tirendi, G.G.; Tarico, M.S.; Curreri, S.; Bonina, F.; Perrotta, R.E. Design of solid lipid nanoparticles for caffeine topical administration. Drug Deliv., 2014, DOI: 10.3109/10717544.2014.903011.
35. Müller, R.H., Olbrich, C. Lipid matrix-drug conjugates particle for controlled release of active ingredient. US6770299; 2004.
36. Olbrich, C.; Gessner, A.; Kayser, O.; Müller, R.H. Lipid-Drug-Conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J. Drug Target., 2002, 10, 387-396.
37. Olbrich, C.; Gessner, A.; Schröder, W.; Kayser, O.; Müller, R.H. Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption. J. Control. Release., 2004, 96, 425-435.
38. Paliwal, R.; Rai, S.; Vyas, S.P. Lipid drug conjugate (LDC) nanoparticles as autolymphotrophs for oral delivery of methotrexate. J. Biomed. Nanotechnol., 2011, 7, 130-131.
39. Olbrich, C.; Muller, R.H. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm., 1999, 180, 31-39.
40. Uner, M; Wissing, S.A.; Yener, G; Müller, R.H. Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations. Pharmazie, 2004, 59, 331-332.
41. Lallemand, F.; Daull, P.; Benita, S.; Buggage, R.; Garrigue, J.S. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J. Drug. Deliv., 2012, 2012:604204.
42. Hwang, T.L.; Aljuffali, I.A.; Lin, C.F.; Chang, Y.T.; Fang, J.Y. Cationic additives in nanosystems activate cytotoxicity and inflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles. Int. J. Nanomedicine, 2015, 10, 371-385.
43. Souza, J.G.; Karina, D.; Pereira, T.A.; Bernardi, D.S.; Lopez, R.F.V. Topical delivery of ocular therapeutics: carrier systems and physical methods. J. Pharm. Pharmacol., 2013, 66, 507-530.
44. Sallam, A.; Jayakumar, S.; Lightman, S. Intraocular delivery of anti-infective drugs-bacterial, viral, fungal and parasitic. Recent Pat. Antiinfect. Drug Discov., 2008, 3, 53-63.
45. Diebold, Y.; Calonge, M. Application on nanoparticles in ophthalmology. Prog. Retin. Eye Res., 2010, 29, 596-609.
46. Anand, R.; Nightingale, S.D.; Fish, R.H.; Smith, T.J.; Ashton, P. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch. Ophthalmol., 1993; 111, 223-227.
47. Yasukawa, T.; Ogura, Y.; Tabata, Y.; Kimura, H.; Wiedemann, P.; Honda, Y. Drug delivery systems for vitreoretinal diseases. Prog. Retin. Eye Res., 2004, 23, 253-281.
48. Vandervoort, J.; Ludwig, A. Ocular drug delivery: nano medicine applications. Nanomedicine, 2007, 2, 11-21.
49. Apaolaza, P. S.; Delgado, D.; del Pozo-Rodriguez, A.; Gascon, A.R.; Solinis, M.A. A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases. Int. J. Pharm., 2014, 465(1-2), 413-426.
50. del Pozo-Rodriguez, A.; Delgado, D.; Solinis, M. A.; Gascon, A. R.; Pedraz, J. L. Solid lipid nanoparticles for retinal gene therapy: Transfection and intracellular trafficking in retinal pigment epithelial cells. Int. J. Pharm., 2008, 360(1-2), 177-183.
51. Scott, I.U.; Flynn, H.W. Jr; Rosenfeld, P.J. Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema. Am. J. Ophthalmol., 2003, 136(4), 737-739.
52. Felt-Baeyens, O.; Eperon, S.; Mora, P.; Limal, D.; Sagodira, S.; Breton, P.; Simonazzi, B.; Bossy-Nobs, L.; Guex-Crosier, Y.; Gurny, R. Biodegradable scleral implants as new triamcinolone acetonide delivery systems. Int. J. Pharm., 2006, 322(1-2), 6-12.
53. Araújo, J.; Gonzalez-Mira, E.; Egea, M.A.; Garcia, M.L.; Souto, E.B. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int. J. Pharm., 2010, 393(1-2), 167-175.
54. Araújo, J.; Nikolic, S.; Egea, M.A.; Souto, E.B.; Garcia, M.L. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf. B., 2011, 88(1), 150-157.
55. Araújo, J.; Garcia, M.L.; Mallandrich, M.; Souto, E.B.; Calpena, A.C. Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. Nanomedicine, 2012, 8(6), 1034-1041.
56. Almeida, D.R.; Johnson, D.; Hollands, H.; Smallman, D.; Baxter, S.; Eng, K.T.; Kratky V.; ten Hove M.W.; Sharma S.; El-Defrawy, S. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. J. Cataract Refr. Surg., 2008, 34, 64-69.
57. Sengupta, S.; Subramoney, K.; Srinivasan, R.; Nongrum, B.; Agarwal, V.; Pandian, D.G.; Suchismitha, T.; Kaliaperumal, S. Use of a mydriatic cocktail with a wick for preoperative mydriasis in cataract surgery: A prospective randomised controlled trial, Eye (Lond.), 2010, 24, 118-122.
58. Li, X.; Nie, S.F.; Kong, J.; Li, N.; Ju, C.Y.; Pan, W.S. A controlledrelease ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int. J. Pharm., 2008, 363(1-2), 177-182.
59. Attama, A.A.; Reichl, S.; Müller-Goymann, C.C. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int. J. Pharm., 2008, 355(1-2), 307-313.
60. Chetoni, P.; Panichi, L.; Burgalassi, S.; Benelli, U.; Saettone, M.F. Pharmacokinetics and anti-inflammatory activity in rabbits of a novel indomethacin ophthalmic solution. J. Ocul. Pharmacol. Ther., 2000, 16(4), 363-372.
61. Hippalgaonkar, K.; Adelli, G.R.; Hippalgaonkar, K.; Repka, M.A.; Majumdar, S. Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation. J. Ocul. Pharmacol. Ther., 2013, 29(2), 216-228.
62. Gonzalez-Mira, E.; Nikolić, S.; Calpena, A.C.; Egea, M.A.; Souto, E.B.; García, M.L. Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogels. J. Pharm. Sci., 2012, 101(2), 707-725.
63. Gonzalez-Mira, E.; Egea, M.A.; Souto, E.B.; Calpena, A.C.; García, M.L. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology, 2011, 22(4), 045101.
64. Luo, Q.; Zhao, J.; Zhang, X.; Pan, W. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int. J. Pharm., 2011, 403(1-2), 185-191.
65. Tian, B.; Luo, Q.; Song, S.; Liu, D.; Pan, H.; Zhang, W.; He, L.; Ma, S.; Yang, X.; Pan, W. Novel surface-modified nanostructured lipid carriers with partially deacetylated water-soluble chitosan for efficient ocular delivery. J. Pharm. Sci., 2012, 101(3), 1040-1049.
66. Shaikh, M.Y.; Mars, J.S.; Heaven, C.J. Prednisolone and flurbiprofen drops to maintain mydriasis during phacoemulsification cataract surgery. J. Cataract Refract. Surg., 2003, 29(12), 2372-2377.
67. Gokce, E.H.; Sandri, G.; Bonferoni, M. C.; Rossi, S.; Ferrari, F.; Gueneri, T.; Caramella, C. Cyclosporine A loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity. Int. J. Pharm., 2008, 364(1), 76-86.
68. Niu, M.; Shi, K.; Sun, Y.; Wang, J.; Cui, F. Preparation of CyAloaded solid lipid nanoparticles and application on ocular preparations. J. Drug Del. Sci. Tech., 2008, 18(4), 293-297.
69. Goekce, E. H.; Sandri, G.; Egrilmez, S.; Bonferoni, M. C.; Gueneri, T.; Caramella, C. Cyclosporine A-Loaded Solid Lipid Nanoparticles: Ocular Tolerance and In vivo Drug Release in Rabbit Eyes. Curr. Eye Res., 2009, 34(11), 996-1003.
70. Sandri, G.; Bonferoni, M.C.; Gokce, E.H.; Ferrari, F.; Rossi, S.; Patrini, M.; Caramella, C. Chitosan-associated SLN: In vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems. J. Microencapsul., 2010, 27(8), 735-746.
71. Basaran, E.; Demirel, M.; Sirmagul, B.; Yazan, Y. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J. Microencapsul., 2010, 27(1), 37-47.
72. Shen, J.; Deng, Y.; Jin, X.; Ping, Q.; Su, Z.; Li, L. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution. Int. J. Pharm., 2010, 402(1-2), 248-253.
73. Shen, J.; Sun, M.; Ping, Q.; Ying, Z.; Liu, W. Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement. Nanotechnology, 2010, 21(2), 025101/1-025101/10.
74. Battaglia, L.; D'Addino, I.; Peira, E.; Trotta, M.; Gallarate, M. Solid lipid nanoparticles prepared by coacervation method as vehicles for ocular cyclosporine. J. Drug Del. Sci. Tech., 2012, 22(2), 125-130.
75. Carbone, C.; Tomasello, B.; Ruozi, B.; Renis, M.; Puglisi, G. Preparation and optimization of PIT solid lipid nanoparticles via statistical factorial design. Eur. J. Med. Chem., 2012, 49, 110-117.
76. Carbone, C.; Campisi, A.; Manno, D.; Serra, A.; Spatuzza, M.; Musumeci, T.; Bonfanti, R.; Puglisi, G. The critical role of didodecyldimethylammonium bromide on physico-chemical, technological and biological properties of NLC. Colloids Surf. B. Biointerfaces, 2014, 121, 1-10.
77. Leonardi, A.; Crasci', L.; Panico, A.; Pignatello, R. Antioxidant activity of idebenone-loaded neutral and cationic solid-lipid nanoparticles. Pharm. Dev. Technol., 2014, doi:10.3109/10837450.2014.915572.
78. Fangueiro, J.F.; Andreani, T.; Egea, M.A.; Garcia, M. L.; Souto, S.B.; Silva, A. M.; Souto, E.B. Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity, Int. J. Pharm., 2014, 461(1-2), 64-73.
79. Abul Kalam, M.; Sultana, Y.; Ali, A.; Aqil, M.; Mishra, A.K.; Aljuffali, I.A.; Alshamsan, A. Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin. J. Biomed. Mater. Res. A., 2013, 101(6), 813-827.
80. Abul Kalam, M.; Sultana, Y.; Ali, A.; Aqil, M.; Mishra, A.K.; Chuttani, K.; Aljuffali, I.A.; Alshamsan, A. Part II: Enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops. J. Biomed. Mater. Res. A., 2013, 101(6), 1828-36.
81. Shen, J.; Wang, Y.; Ping, Q.; Xiao, Y.; Huang, X. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J. Control. Release, 2009, 137(3), 217-223.
82. Cavalli, R.; Gasco, M. R.; Chetoni, P.; Burgalassi, S.; Saettone, M. F. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm., 2002, 238(1-2), 241-245.
83. Kalam, M. A.; Sultana, Y.; Ali, A.; Aqil, M..; Mishra, A. K.; Chuttani, K. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J. Drug Target., 2010, 18(3), 191-204.
84. Hao, J.; Fang, X.; Zhou, Y.; Wang, J.; Guo, F.; Li, F.; Peng, X. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int. J. Nanomedicine, 2011, 6, 683-692.
85. Wu, J.W.; Xia, Q. Preparation and characterization of azithromycin-loaded nanostructured lipid carriers. Adv. Mater. Res., 2011, 236-238.
86. Ustündaʇ-Okur, N.; Gökçe, E.H.; Bozbiyik, D.I.; Eʇrilmez, S.; Ozer, O.; Ertan, G. Preparation and in vitro-in vivo evaluation of ofloxacin loaded ophthalmic nano structured lipid carriers modified with chitosan oligosaccharide lactate for the treatment of bacterial keratitis. Eur. J. Pharm. Sci., 2014, 63, 204-215.
87. Law, S.L.; Huang, K.J.; Chiang, C.H. Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. J. Control. Release, 2000, 63, 135-140.
88. de Jalòn, E.G.; Blanco-Prìeto, M.J.; Ygartua, P.; Santoyo, S. Increased efficacy of acyclovir-loaded microparticles against herpes simplex virus type I in cell cultures. Eur. J. Pharm. Biopharm., 2003, 53, 183-187.
89. Vadlapudi, A.D.; Vadlapatla, R.K.; Kwatra, D.; Earla, R.; Samanta, S.K.; Pal, D.; Mitra, A.K. Targeted lipid based drug conjugates: A novel strategy for drug delivery. Int. J. Pharm., 2012, 434(1-2), 315-324.
90. Seyfoddin, A.; Al-Kassas, R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev. Ind. Pharm., 2013, 39(4), 508-519.
91. Adedayo, A. Ocular Diseases, 1st ed.; In Tech, 2012.
92. Attama, A. A.; Reichl, S.; Mueller-Goymann, C. C. Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr. Eye Res., 2009, 34(8), 698-705.
93. Youshia, J.; Kamel, A.O.; El Shamy, A.; Mansour, S. Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide. Int. J. Nanomedicine., 2012, 7, 2483-2496.
94. Wang, F.; Chen, L.; Jiang, S.; He, J.; Zhang, X.; Peng, J.; Xu, Q.; Li, R. Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design. J. Liposome Res., 2014, 24(3); 171-181.
95. Wang, F.; Chen, L.; Zhang, D.; Jiang, S.; Shi, K.; Huang, Y.; Li, R.; Xu, Q. Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: in vitro and in vivo study. J. Drug Target., 2014, 22(9); 849-858.
96. Luetfi, G.; Muezeyyen, D. Preparation and characterization of polymeric and lipid nanoparticles of pilocarpine HCl for ocular application. Pharmaceut. Dev. Tech., 2013, 18(3), 701-709.
97. Musumeci, T.; Bucolo, C.; Carbone, C.; Pignatello, R.; Drago, F.; Puglisi G. Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. Int. J. Pharm., 2013, 440(2), 135-140.
98. Jiang, M.; Gan, L.; Zhu, C.; Dong, Y.; Liu, J.; Gan, Y. Cationic core-shell liponanoparticles for ocular gene delivery. Biomaterials, 2012, 33(30), 7621-7630.
99. Delgado, D; del Pozo-Rodriguez, A.; Solinis, M.A.; Rodriguez-Gascon, A. Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: The importance of the entry pathway. Eur. J. Pharm. Biopharm., 2011, 79(3), 495-502.
100. Spalton, D.J. Posterior capsular opacification after cataract surgery. Eye (Lond)., 1999, 13, 489-492.
101. Zhang, W.; Li, X.; Ye, T.; Chen, F.; Sun, X.; Kong, J.; Yang, X.; Pan, W.; Li, S. Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology. Int. J. Pharm., 2013, 454(1), 354-366.
102. Zhang, W.; Liu, J.; Zhang, Q.;, Li, X.;, Yu, S.;, Yang, X.;, Kong, J.;, Pan, W. Enhanced cellular uptake and anti-proliferating effect of chitosan hydrochlorides modified genistein loaded NLC on human lens epithelial cells. Int. J. Pharm., 2014, 471(1-2), 118-126.
103. Walker, J.L.; Wolff, I.M.; Zhang, L.; Menko, A.S. Activation of SRC kinases signals induction of posterior capsule opacification. Invest. Ophthalmol. Vis. Sci., 2007, 48(5), 2214-2223.
104. Hartong, D.T.; Berson, E.L.; Dryja, T.P. Retinitis pigmentosa. Lancet, 2006, 368(9549):1795-1809.
105. Rotstein, N.P.; Miranda, G.E.; Abrahan, C.E.; German, O.L. Regulating survival and development in the retina: key roles for simple sphingolipids. J. Lipid Res., 2010, 51(6), 1247-1262.
106. Strettoi, E.; Gargini, C.; Novelli, E.; Sala, G.; Piano, I.; Gasco, P.; Ghidoni, R. Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosa. Proc. Natl. Acad. Sci. U S A., 2010, 107(43), 18706-18711.
107. Liu, R.; Liu, Z.; Zhang, C.; Zhang, B. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability. J. Pharm. Sci., 2012, 101(10), 3833-3844.
108. Liu, Z.; Zhang, X.; Wu, H.; Li, J.; Shu, L.; Liu, R.; Li, L.; Li, N. Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug Dev. Ind. Pharm., 2011, 37(4), 475-481.
109. Gupta, D.; Bleakley, B.; Gupta, R.K. Dragon's blood: botany, chemistry and therapeutic uses. J. Ethnopharmacol., 2008, 115(3), 361-380.
110. Hao, J.; Wang, X.; Bi, Y.; Teng, Y.; Wang, J.; Li, F.; Li, Q.; Zhang, J.; Guo, F.; Liu, J. Fabrication of a composite system combining solid lipid nanoparticles and thermosensitive hydrogel for challenging ophthalmic drug delivery. Colloids Surf. B. Biointerfaces, 2014, 114, 111-20.
111. Pignatello R.; Puglisi, G. Nanotechnology in ophthalmic drug delivery: A survey of recent developments and patenting activity. Recent Patents Nanomed., 2011, 1, 42-52.
112. Keck, C. M.; Hommoss, A.; Müller, R. H. Lipid nanoparticles (SLN, NLC, LDC) for the enhancement of oral absorption. In: Modified Release Drug Delivery Technology Vol. 2; Rathbone, M. J. Ed.;, Informa Healthcare, 2008.